01:21 , Dec 8, 2018 |  BioCentury  |  Strategy

Novo gets serious about AI-guided drug design

Novo Nordisk A/S is fashioning its R&D makeover to integrate artificial intelligence across its drug discovery and development process, after a pilot program delivered the cost and time savings the pharma was looking for. In...
18:36 , Nov 30, 2018 |  BC Week In Review  |  Clinical News

Novo’s oral GLP-1 analog as add-on to insulin meets in Phase IIIa for Type II diabetes

Novo Nordisk A/S (CSE:NOVO B; NYSE:NVO) reported top-line data on Oct. 26 showing that oral semaglutide met the primary endpoint in the Phase IIIa PIONEER 8 trial to treat Type II diabetes in patients treated...
18:34 , Nov 30, 2018 |  BC Week In Review  |  Clinical News

Novo to seek semaglutide approvals on new CVOT data

Novo Nordisk A/S (CSE:NOVO B; NYSE:NVO) said it will submit regulatory applications next half in the U.S. and EU for once-daily oral semaglutide after reporting the compound met the primary endpoint in the Phase IIIa...
21:40 , Nov 26, 2018 |  BC Extra  |  Clinical News

Novo to seek semaglutide approvals on new CVOT data

Novo Nordisk A/S (CSE:NOVO B; NYSE:NVO) said it will submit regulatory applications next half in the U.S. and EU for once-daily oral semaglutide after reporting the compound met the primary endpoint in the Phase IIIa...
19:59 , Nov 16, 2018 |  BioCentury  |  Tools & Techniques

Benchtop manufacturing gets smaller

Publisher’s note: This story originally ran in the Nov. 15, 2018 issue of BioCentury Innovations , a comprehensive source of developments in translational research with knowledgeable perspectives on the key innovations, trends and opportunities in...
22:43 , Nov 15, 2018 |  BC Innovations  |  Tools & Techniques

Benchtop manufacturing gets smaller

MIT scientists continue to break new ground in benchtop manufacturing systems for biologics. Published in Nature Biotechnology last month, the latest advance from the institute centered on an automated, closed system capable of producing clinical-grade...
22:54 , Nov 9, 2018 |  BioCentury  |  Product Development

Cashing out CVOT

Whether or how much diabetes companies will save by dropping postmarket cardiovascular outcomes trials, if FDA follows the advice of its advisory committee, could boil down to what target they are pursuing and whether they...
19:07 , Nov 9, 2018 |  BC Innovations  |  Distillery Techniques

Chemistry; drug platforms

TECHNOLOGY: Synthetic chemistry; conjugates A method for linking methionine residues to small molecules could be used to generate novel therapeutic protein-drug conjugates. The method involves two steps: adding a diazo-iodonium salt to a protein or...
19:55 , Nov 8, 2018 |  BC Innovations  |  Emerging Company Profile

Abarceo: restoring beta cell function

Abarceo Pharma AB has identified VDAC1 as a key target in Type II diabetes, and is developing antibodies and small molecule inhibitors against the target as durable and disease-modifying treatments. Standard first-line therapy for Type...
19:44 , Nov 6, 2018 |  BC Innovations  |  Distillery Techniques

Drug delivery

TECHNOLOGY: Targeting domains Conjugating ASOs to a GLP-1R agonist construct could enhance the delivery of antisense therapies to pancreatic islet β cells for metabolic diseases. The conjugates consist of 5’-hexylamino ASOs against the selected therapeutic...